

We claim:

1. A crystalline tegaserod maleate Form I, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 5.3, 5.9, 6.4, 10.7, 16.1 and 26.8 degrees.
5
2. A crystalline tegaserod maleate Form I as defined in claim 1, further characterized by an x-ray powder diffraction pattern as in figure 1.
3. A process for preparation of tegaserod maleate Form I as defined in claim 1, which comprises:
10
 - a) adding maleic acid to a solution of tegaserod free base in acetone; and
 - b) Isolating tegaserod maleate Form I.
4. A process for preparation of tegaserod maleate Form I as defined in claim 1, which comprises mixing tegaserod maleate and acetone and collecting tegaserod maleate Form I by filtration.
- 15 5. A crystalline tegaserod maleate Form II, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 5.3, 6.4, 6.9, 7.8, 8.7, 10.2, 10.8, 15.5, 16.8, 17.0, 19.5, 21.2, 21.7, 22.7 and 25.2 degrees.
6. A crystalline tegaserod maleate Form II as defined in claim 5, further characterized by an x-ray powder diffraction pattern as in figure 2.
- 20 7. A process for preparation of tegaserod maleate Form II as defined in claim 5, which comprises:
 - a) dissolving tegaserod maleate in methanol; and
 - b) precipitating tegaserod maleate Form II from the solution by mixing with acetonitrile;
- 25 8. A crystalline tegaserod maleate Form III, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 7.0, 7.9, 8.7, 10.2, 15.6, 15.9, 17.0, 19.5, 25.3 and 27.1 degrees.
9. A crystalline tegaserod maleate Form III as defined in claim 8, further characterized by an x-ray powder diffraction pattern as in figure 3.
- 30 10. A process for preparation of tegaserod maleate Form III as defined in claim 8, which comprises:
 - a) mixing maleic acid and a solution of tegaserod free base in methanol; and
 - b) collecting the solid separated by filtration.

11. A process for the preparation of tegaserod maleate Form III as defined in claim 8, which comprises;
- a) dissolving tegaserod maleate in methanol;
 - b) maintaining for about 30 minutes at about 20°C to 25°C; and
 - 5 c) collecting the solid separated by filtration.
12. A crystalline tegaserod maleate Form IV, characterized by an x-ray powder diffraction pattern having peaks expressed as 2θ at about 6.9, 8.0, 10.3, 16.5, 19.6, 20.4, 20.9, 22.0, 23.2, 25.4, 28.0 and 28.7 degrees.
13. A crystalline tegaserod maleate Form IV as defined in claim 12, further
- 10 characterized by an x-ray powder diffraction pattern as in figure 4.
14. A process for preparation of tegaserod maleate Form IV as defined in claim 12, which comprises:
- a) mixing maleic acid and a solution of tegaserod free base in methanol; and
 - b) precipitating tegaserod maleate Form IV by mixing with methylene
 - 15 dichloride or isopropyl alcohol.
15. A pharmaceutical composition comprising crystalline form of tegaserod maleate and a pharmaceutically acceptable carrier.
16. A pharmaceutical composition as defined in claim 15, wherein the crystalline form is tegaserod maleate Form I of claim 1.
- 20 17. A pharmaceutical composition as defined in claim 15, wherein the crystalline form is tegaserod maleate Form II of claim 5.
18. A pharmaceutical composition as defined in claim 15, wherein the crystalline form is tegaserod maleate Form III of claim 8.
19. A pharmaceutical composition as defined in claim 15, wherein the crystalline
- 25 form is tegaserod maleate Form IV of claim 12.